Annual General Meeting ("AGM") and Extraordinary General Meeting ("EGM") Notices Posted to Shareholders
August 15 2007 - 7:03AM
PR Newswire (US)
VALLEY COTTAGE, New York, August 15 /PRNewswire-FirstCall/ -- XTL
Biopharmaceuticals Ltd. (NASDAQ:XTLB)(LSE:XTL)(TASE:XTL), a
biopharmaceutical company engaged in the acquisition, development
and commercialization of therapeutics for the treatment of unmet
medical needs, particularly neuropathic pain and hepatitis C, today
announced its has posted to shareholders a notice convening its AGM
and EGM. The AGM and EGM will take place at the Conference Room at
the Company's Israeli offices at Building 3, Kiryat Weizmann
Science Park, Rehovot, Israel 76100, at 4:00 p.m. Israel time, and
4:30pm Israel time, respectively, on September 25, 2007. At the AGM
it is proposed that: - the annual reports for the year ended 31
December 2006 be received; - Kesselman & Kesselman
(PricewaterhouseCoopers) be reappointed as the Company's auditors
and the fixing of their remuneration be authorized; and - Messrs
Michael Weiss, Ben Zion Weiner and William Kennedy be re-appointed
as Directors of the Company. At the EGM it is proposed that: - the
registered share capital of the Company be increased from
300,000,000 Ordinary Shares to 500,000,000 Ordinary Shares, NIS
0.02 nominal value each; and - the listing of the Company's
Ordinary Shares on the Official List of the United Kingdom Listing
Authority be cancelled. About XTL Biopharmaceuticals Ltd. XTL
Biopharmaceuticals Ltd. ("XTL") is engaged in the acquisition,
development and commercialization of therapeutics for the treatment
of neuropathic pain and hepatitis C. XTL is developing Bicifadine,
a serotonin and norepinephrine reuptake inhibitor, for the
treatment of neuropathic pain. XTL is also developing several novel
pre-clinical hepatitis C small molecule inhibitors. XTL also has an
active in-licensing and acquisition program designed to identify
and acquire additional drug candidates. XTL is publicly traded on
the NASDAQ, London, and Tel-Aviv Stock Exchanges (NASDAQ:XTLB) (
LSE: XTL) (TASE:XTL). Contact: Ron Bentsur, Chief Executive Officer
Tel: +1-845-267-0707 ext. 225 +972-8-930-4444 DATASOURCE: XTL
Biopharmaceuticals Ltd CONTACT: Contact: Ron Bentsur, Chief
Executive Officer, Tel: +1-845-267-0707 ext. 225, +972-8-930-4444
Copyright
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jun 2024 to Jul 2024
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jul 2023 to Jul 2024